What is HGH Frag 176-191 CJC-1295 DAC?
HGH Fragment 176-191 & CJC-1295 DAC combines two well-known research peptides that have distinct effects on growth hormone physiology. While CJC-1295 DAC is a long-acting growth hormone-releasing hormone (GHRH) analogue intended to prolong the body’s natural release of growth hormone, HGH Frag 176-191 is a modified part of the human growth hormone molecule that is being studied primarily for its potential effects on fat metabolism (1). This combination is being investigated to see if the peptides could have complementary impacts on metabolic function and body composition.
Current research is examining HGH Fragment 176-191 & CJC-1295 DAC for its potential applications in fat metabolism, energy regulation, recovery, and changes in lean body composition. Because CJC-1295 DAC promotes sustained growth hormone signalling, researchers are also interested in how it may influence circulating IGF-1 levels when paired with HGH Fragment 176-191 (2).
Potential Applications of HGH Frag 176-191 CJC-1295 DAC
Laboratory studies have demonstrated that HGH Fragment 176-191 CJC-1295 DAC blend peptide could have the following benefits:
Potential Support for Fat Metabolism – HGH Fragment 176-191 is being investigated for its ability to influence fat breakdown (lipolysis), while CJC-1295 DAC may enhance growth hormone activity, making the combination of interest in metabolic research (1).
Body Composition Research – Researchers are studying whether this blend may help improve the lean-to-fat mass ratio through complementary mechanisms involving growth hormone signalling and fat metabolism.
Sustained Growth Hormone Release: By stimulating the body’s natural growth hormone production for an extended period of time, CJC-1295 DAC enables researchers to investigate the consequences of sustained GH elevation.
IGF-1 Regulation Studies – The blend is being explored for its potential to increase circulating insulin-like growth factor-1 (IGF-1), an important mediator of many growth hormone-related physiological processes (2).
Research on Exercise Recovery: Since growth hormone is involved in tissue maintenance and repair, scientists are looking into the possibility that this peptide combination could aid in recovery after physical activity.
Metabolic Health Applications – Early studies are evaluating how enhanced growth hormone activity may influence energy expenditure, nutrient utilisation, and overall metabolic function (3).
Research on HGH Fragment 176-191 CJC-1295 DAC
Research into the HGH Fragment 176-191 & CJC-1295 DAC blend focuses on how two complementary peptide mechanisms may influence growth hormone physiology, body composition, and metabolic function. Although relatively few studies have examined the combination directly, there is a substantial body of research investigating each peptide individually. Researchers are using this blend to explore whether combining a fat metabolism-focused peptide with a long-acting growth hormone-releasing hormone (GHRH) analogue produces additive or complementary physiological effects.
A modified section of the human growth hormone molecule called HGH Fragment 176–191 has been examined mainly for its possible function in promoting lipolysis while reducing the more extensive biological effects of full-length growth hormone. Larger human studies are required to validate preclinical evidence that suggests it may enhance fat metabolism without substantially altering blood glucose regulation (1).
Due to its Drug Affinity Complex (DAC) technology, CJC-1295 DAC has been studied more thoroughly in early clinical trials, where it has shown the capacity to raise circulating growth hormone and insulin-like growth factor-1 (IGF-1) levels for extended periods of time. Because of its prolonged activity, it is a useful research tool for examining the effects of continuous growth hormone signaling on tissue maintenance, metabolism, and recuperation.
Current scientific interest in the HGH Fragment 176-191 & CJC-1295 DAC blend centres on whether the peptides work synergistically to support favourable changes in body composition, energy metabolism, and recovery-related processes (3). However, direct clinical evidence evaluating the blend remains limited, and further well-designed human studies are required to establish its long-term safety, mechanisms of action, and potential therapeutic applications.
Comparing HGH Fragment 176-191 & CJC-1295 DAC
Feature HGH Fragment 176-191 CJC-1295 DAC Peptide Type Modified fragment of human growth hormone (amino acids 176-191) Long-acting Growth Hormone-Releasing Hormone (GHRH) analogue with Drug Affinity Complex (DAC) Primary Mechanism Studied for its direct effects on fat metabolism Stimulates the pituitary gland to increase natural growth hormone secretion Main Research Focus Fat loss, lipolysis, and body composition Growth hormone release, IGF-1 production, recovery, and healthy ageing Effect on Growth Hormone Does not directly stimulate growth hormone release Increases endogenous growth hormone secretion over an extended period Effect on IGF-1 Little or no direct effect on IGF-1 Increases circulating IGF-1 through sustained growth hormone stimulation Potential Fat Metabolism Effects Primary area of research, with studies focusing on fat breakdown while preserving lean tissue May support fat metabolism indirectly through elevated growth hormone levels Potential Muscle Support Not primarily researched for muscle growth Studied for its ability to support lean muscle maintenance through increased GH and IGF-1 Duration of Action Relatively short-acting Long-acting due to the Drug Affinity Complex (DAC), allowing prolonged activity Common Research Applications Obesity, metabolic health, body composition, and fat metabolism Growth hormone deficiency research, healthy ageing, exercise recovery, body composition, and metabolic function Can They Be Combined? Yes. Researchers often combine HGH Fragment 176-191 with CJC-1295 DAC to investigate whether targeted fat metabolism and sustained growth hormone release produce complementary effects on body composition and metabolic health.
HGH Frag CJC-1295 DAC FAQs
HGH Fragment 176-191 and CJC-1295 DAC have different mechanisms of action. HGH Fragment 176-191 is being studied primarily for its potential effects on fat metabolism, whereas CJC-1295 DAC is a long-acting GHRH analogue that stimulates the body’s natural production of human growth hormone and can increase IGF-1 levels. When combined, researchers investigate whether they may produce complementary effects on body composition and metabolism.
Yes, this peptide blend is being studied for its potential role in fat loss research. HGH Fragment 176-191 has been investigated for its ability to promote lipolysis, while CJC-1295 DAC may support metabolic processes through sustained growth hormone release. However, more high-quality human studies are needed to determine the effectiveness of this combination.
The increase in growth hormone is primarily attributed to CJC-1295 DAC, which stimulates the pituitary gland to release more endogenous growth hormone over an extended period. HGH Fragment 176-191 does not stimulate growth hormone secretion itself but is being researched for its downstream effects on fat metabolism. As a result, any increase in growth hormone observed with the blend is largely due to the CJC-1295 DAC component.
Unlike full-length growth hormone, HGH Fragment 176-191 has been designed to retain fat metabolism-related activity while minimising effects on blood glucose regulation. Early research suggests it may have a limited impact on blood sugar levels, but the available human evidence remains limited. Further clinical studies are required to better understand its metabolic effects.
Because growth hormone is involved in tissue repair, protein synthesis, and recovery processes, researchers are looking at this peptide blend for its possible role in exercise recovery. While HGH Fragment 176-191 is primarily studied for its effects on body composition and energy metabolism, CJC-1295 DAC may support these mechanisms by increasing endogenous growth hormone levels. Despite these encouraging results, there is still no direct clinical support for the combination.
Further Reading
References:
(1) Habibullah MM, Mohan S, Syed NK, Makeen HA, Jamal QMS, Alothaid H, Bantun F, Alhazmi A, Hakamy A, Kaabi YA, Samlan G, Lohani M, Thangavel N, Al-Kasim MA. Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells. Drug Des Devel Ther. 2022 Jun 27;16:1963-1974.
(2) Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805.
(3) Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001 Dec;142(12):5182-9.
Useful Links
Shop Research Peptides with PharmaGrade.Store View an Introduction to Peptides Discover more Frequently Asked Questions about Peptides Find more Pepide Blends Shop Laboratory Consumables View Carefully Selected Peptide Stacks
Buy HGH Frag 176-191 CJC-1295 DAC from PharmaGrade.Store
Laboratory Tested Peptides
Shipping Worldwide
Great Customer Service
All Orders Tracked
Highest Quality 98%+ Purity
ALL PRODUCT INFORMATION AND ARTICLES ON THIS SITE ARE FOR EDUCATIONAL PURPOSES ONLY
DISCLAIMER: All products sold by PharmaGrade.Store are for research and laboratory use only. These products are not designed for use or consumption by humans or animals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such. By purchasing from our Website the buyer accepts and acknowledges the risks involved with handling of these products. All articles and product information provided on this Website are for informational and educational purposes only. Handling and use of these products should be restricted to suitably qualified professionals